Clinical and Diagnostic Laboratory Immunology, 09 1997, 499-503, Vol 4, No. 5
MM Herremans, AM van Loon, JH Reimerink, HC Rumke, HG van der Avoort, TG Kimman and MP Koopmans
In The Netherlands the inactivated poliovirus vaccine (IPV) is used for
protection against poliomyelitis. It is not clear if parenteral vaccination
with IPV can lead to priming of the mucosal immune system. We developed and
evaluated enzyme-linked immunosorbent assays for the detection of
poliovirus serotype-specific immunoglobulin A (IgA) and secretory IgA
antibodies. Using these assays we examined the kinetics of the IgA response
in sequential serum samples from 15 poliomyelitis patients after natural
infection with serotype 3 poliovirus. In 36% of the patients IgA remained
present for up to 5 months postinfection. Furthermore, we examined, in an
IPV-vaccinated population, the presence of IgA antibodies in sera from
young children (4 to 12 years of age; n = 177), sera from older children
(between 13 and 15 years of age; n = 123), sera from healthy blood donors
(n = 66), and sera from naturally immune elderly persons (n = 54). The
seroprevalence of IgA to all three serotypes was low in young vaccinated
children (5 to 7%), and the seroprevalence of IgA types 2 and 3 was low in
older vaccinated children (2 to 3%). The seroprevalence of antibodies to
type 1 was significantly higher (18%) in older children than in younger
children. This higher seroprevalence is most likely explained by the
persistence of IgA following infection with the serotype 1 wild-type
poliovirus strain during the 1978 epidemic. In healthy adults, the
seroprevalence of type 1- and type 2-specific IgA was significantly higher
than that in young children. These results suggest that at least part of
the IgA found in the older population is induced by infections unrelated to
the IPV vaccination schedule. Finally, we found that parenteral vaccination
with IPV was able to boost secretory IgA responses in 74 to 87% of a
naturally exposed elderly population (n = 54). While the presence of
secretory IgA in IPV-vaccinated persons has been documented previously, our
findings suggest that mucosal priming with live virus is necessary to
obtain an IgA response after IPV booster vaccination.
Copyright © 1997 by the American Society for Microbiology. All rights reserved.
Poliovirus-specific immunoglobulin A in persons vaccinated with inactivated poliovirus vaccine in The Netherlands
Research Laboratory for Infectious Diseases, National Institute of Public Health and the Environment, Bilthoven, The Netherlands. Tineke.Herremans@rivm.nl
This article has been cited by other articles:
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. | Infect. Immun. |
|---|---|---|
| J. Clin. Microbiol. | J. Virol. | ALL ASM JOURNALS |